|
ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract Clinical research trials and ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract. ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract clinical trial. Human subjects often get the best healthcare available for their ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "Z" Clinical Trials Conditions > ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract  ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
For Condition: transitional cell carcinoma of the bladder,urethral cancer associated with invasive bladder cancer,recurrent transitional cell cancer of the renal pelvis and ureter,metastatic transitional cell cancer of the renal pelvis and ureter,recurrent bladder cancer,stage 4 bladder cancer,recurrent urethral cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Southwest Oncology Group
Synopsis: RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of cancer of the urinary tract. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have advanced cancer of the urinary tract.
Details: OBJECTIVES: I. Determine the 6-month progression-free survival rate of patients with advanced transitional cell carcinoma of the urothelium treated with ZD 1839. II. Determine the overall survival and response (confirmed complete and partial response) in these patients treated with this regimen. III. Determine the qualitative and quantitative toxicity of this regimen in these patients. IV. Evaluate the changes in growth factor protein kinase expression before and after treatment and at the time of disease progression in these patients treated with this regimen. PROTOCOL OUTLINE: Patients receive oral ZD 1839 daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 months until 3 years after registration. PROJECTED ACCRUAL: A total of 30-55 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed transitional cell carcinoma of the urothelium (bladder, renal pelvis, ureter, or urethra) not curable by surgery or radiotherapy; Any T, N0-3, M1 or unresectable M0 - Measurable disease; At least 1 lesion accessible for biopsy; At least 2 months since prior radiotherapy to target lesion - Progressive or recurrent disease after only 1 prior systemic chemotherapy regimen for advanced disease --Prior/Concurrent Therapy-- - Biologic therapy: No concurrent filgrastim (G-CSF) - Chemotherapy: See Disease Characteristics; No prior adjuvant chemotherapy; At least 28 days since prior chemotherapy and recovered - Endocrine therapy: Not specified - Radiotherapy: See Disease Characteristics; At least 28 days since prior radiotherapy and recovered - Surgery: See Disease Characteristics; At least 28 days since prior surgery and recovered - Other: No systemic therapy between biopsy and study entry; At least 28 days since prior intravesical therapy and recovered --Patient Characteristics-- - Age: Any age - Performance status: Zubrod 0-2 - Life expectancy: Not specified - Hematopoietic: Platelet count at least 100,000/mm3; Absolute granulocyte count at least 1,200/mm3 - Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN); SGOT no greater than 2 times ULN - Renal: Creatinine no greater than 2 times ULN - Other: No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission; Not pregnant or nursing; Fertile patients must use effective contraception
Total Enrollment:
Location and Contact Information:
Overall Study Official:
DanielPetrylak, Study Chair, Southwest Oncology Group
Veterans Affairs Medical Center - Shreveport
Shreveport, Louisiana, 71130
United States
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
United States
CCOP - Southeast Cancer Control Consortium
Winston Salem, North Carolina, 27104-4241
United States
CCOP - St. Louis-Cape Girardeau
St. Louis, Missouri, 63141
United States
Baylor College of Medicine
Houston, Texas, 77030
United States
CCOP - Virginia Mason Research Center
Seattle, Washington, 98101
United States
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
United States
Providence Hospital - Southfield
Southfield, Michigan, 48075-9975
United States
CCOP - Greater Phoenix
Phoenix, Arizona, 85006-2726
United States
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, 35294-3300
United States
Arizona Cancer Center
Tucson, Arizona, 85724
United States
David Grant Medical Center
Travis Air Force Base, California, 94535
United States
Veterans Affairs Medical Center - Little Rock (McClellan)
Little Rock, Arkansas, 72205
United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78284-7811
United States
Veterans Affairs Medical Center - Cincinnati
Cincinnati, Ohio, 45220-2288
United States
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
United States
Texas Tech University Health Science Center
Lubbock, Texas, 79415
United States
Veterans Affairs Medical Center - Oklahoma City
Oklahoma City, Oklahoma, 73104
United States
Cancer Research Center of Hawaii
Honolulu, Hawaii, 96813
United States
CCOP - Greenville
Greenville, South Carolina, 29615
United States
Dwight David Eisenhower Army Medical Center
Fort Gordon, Georgia, 30905-5650
United States
Veterans Affairs Medical Center - Kansas City
Kansas City, Missouri, 64128
United States
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90033-0804
United States
Veterans Affairs Medical Center - Boston (Jamaica Plain)
Jamaica Plain, Massachusetts, 02130
United States
University of Colorado Cancer Center
Denver, Colorado, 80010
United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379
United States
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
CCOP - Columbia River Program
Portland, Oregon, 97213
United States
Loyola University Medical Center
Maywood, Illinois, 60153
United States
CCOP - Ann Arbor Regional
Ann Arbor, Michigan, 48106
United States
Veterans Affairs Medical Center - Temple
Temple, Texas, 76504
United States
CCOP - Toledo Community Hospital Oncology Program
Toledo, Ohio, 43623-3456
United States
Veterans Affairs Medical Center - San Francisco
San Francisco, California, 94121
United States
Keesler Medical Center - Keesler AFB
Keesler AFB, Mississippi, 39534-2576
United States
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234
United States
Henry Ford Hospital
Detroit, Michigan, 48202
United States
Barrett Cancer Center, The University Hospital
Cincinnati, Ohio, 45267-0502
United States
CCOP - Wichita
Wichita, Kansas, 67214-3882
United States
Louisiana State University Health Sciences Center - Shreveport
Shreveport, Louisiana, 71130-3932
United States
Veterans Affairs Medical Center - Denver
Denver, Colorado, 80220
United States
Eastern Virginia Medical School
Norfolk, Virginia, 23507
United States
Albert B. Chandler Medical Center, University of Kentucky
Lexington, Kentucky, 40536-0084
United States
MBCCOP - LSU Health Sciences Center
New Orleans, Louisiana, 70112
United States
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65807
United States
CCOP - Duluth
Duluth, Minnesota, 55805
United States
Veterans Affairs Medical Center - Lexington
Lexington, Kentucky, 40511-1093
United States
Veterans Affairs Medical Center - Dallas
Dallas, Texas, 75216
United States
Veterans Affairs Medical Center - Seattle
Seattle, Washington, 98108
United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
United States
Veterans Affairs Medical Center - Wichita
Wichita, Kansas, 67218
United States
Veterans Affairs Medical Center - Phoenix (Hayden)
Phoenix, Arizona, 85012
United States
CCOP - Kansas City
Kansas City, Missouri, 64131
United States
CCOP - Columbus
Columbus, Ohio, 43206
United States
MBCCOP - University of New Mexico HSC
Albuquerque, New Mexico, 87131
United States
Veterans Affairs Outpatient Clinic - Martinez
Martinez, California, 94553
United States
Tulane University School of Medicine
New Orleans, Louisiana, 70112
United States
Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
Hines, Illinois, 60141
United States
Veterans Affairs Medical Center - Albuquerque
Albuquerque, New Mexico, 87108-5138
United States
MBCCOP - University of Illinois at Chicago
Chicago, Illinois, 60612-7323
United States
Cancer Center and Beckman Research Institute, City of Hope
Duarte, California, 91010-3000
United States
Herbert Irving Comprehensive Cancer Center
New York City, New York, 10032
United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
United States
St. Louis University Health Sciences Center
St. Louis, Missouri, 63110-0250
United States
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California, 95403
United States
Veterans Affairs Medical Center - Jackson
Jackson, Mississippi, 39216
United States
CCOP - Scott and White Hospital
Temple, Texas, 76508
United States
Veterans Affairs Medical Center - New Orleans
New Orleans, Louisiana, 70112
United States
Chao Family Comprehensive Cancer Center
Orange, California, 92868
United States
University of Mississippi Medical Center
Jackson, Mississippi, 39216-4505
United States
CCOP - Dayton
Kettering, Ohio, 45429
United States
Veterans Affairs Medical Center - Portland
Portland, Oregon, 97207
United States
University of Texas Medical Branch
Galveston, Texas, 77555-0209
United States
Veterans Affairs Medical Center - Detroit
Detroit, Michigan, 48201-1932
United States
Veterans Affairs Medical Center - Tucson
Tucson, Arizona, 85723
United States
Veterans Affairs Medical Center - Biloxi
Biloxi, Mississippi, 39531-2410
United States
University of Kansas Medical Center
Kansas City, Kansas, 66160-7357
United States
Veterans Affairs Medical Center - Ann Arbor
Ann Arbor, Michigan, 48105
United States
Huntsman Cancer Institute
Salt Lake City, Utah, 84112
United States
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, 73104
United States
Veterans Affairs Medical Center - Long Beach
Long Beach, California, 90822
United States
Veterans Affairs Medical Center - West Los Angeles
Los Angeles, California, 90073
United States
Veterans Affairs Medical Center - Salt Lake City
Salt Lake City, Utah, 84148
United States
Boston Medical Center
Boston, Massachusetts, 02118
United States
CCOP - Grand Rapids Clinical Oncology Program
Grand Rapids, Michigan, 49503
United States
Oregon Cancer Center
Portland, Oregon, 97201-3098
United States
CCOP - Bay Area Tumor Institute
Oakland, California, 94609-3305
United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0752
United States
University of California Davis Medical Center
Sacramento, California, 95817
United States
Swedish Cancer Institute
Seattle, Washington, 98104
United States
CCOP - Northwest
Tacoma, Washington, 98405-0986
United States
CCOP - Atlanta Regional
Atlanta, Georgia, 30342-1701
United States
CCOP - Central Illinois
Decatur, Illinois, 62526
United States
Veterans Affairs Medical Center - San Antonio (Murphy)
San Antonio, Texas, 78284
United States
MBCCOP - Gulf Coast
Mobile, Alabama, 36688
United States
Madigan Army Medical Center
Tacoma, Washington, 98431-5000
United States
Additional Information:
Study ID Numbers: CDR0000068509; SWOG-S0031
Study Start Date: February 2001
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00014144
Other Transitional Cell Carcinoma Of The Bladder Studies:
1. Trastuzumab in Treating Patients With Previously Treated, Locally Advanced or Metastatic Kidney Cancer
2. Pemetrexed Disodium in Treating Patients With Locally Advanced or Metastatic Recurrent Cancer of the Urothelium
3. Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer
4. ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
5. Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract
Related Studies:
Other transitional cell carcinoma of the bladder Clinical Trials
Other Washington Clinical Trials
Other Seattle Clinical Trials
ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
|
|
|
|
|
|
|
|
